

August 14, 2018

CymaBay Therapeutics to Participate in Upcoming Investor Conferences in August and September

NEWARK, Calif., Aug. 14, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in upcoming investor conferences, including the Wedbush PacGrow Healthcare Conference, the H.C. Wainwright 20th Annual Global Investment Conference, and the Citi's 13th Annual Biotech Conference.

Wedbush PacGrow Healthcare Conference

Date: Wednesday, August 15
Time: 2:30pm Eastern Time
Location: Parker New York, New York, NY
Webcast: <http://ir.cymabay.com/events>

H.C. Wainwright 20th Annual Global Investment Conference

Date: Wednesday, September 5
Time: 9:10am Eastern Time
Location: St. Regis Hotel, New York, NY
Webcast: <http://ir.cymabay.com/events>

Citi's 13th Annual Biotech Conference

Date: Thursday, September 6
Time: 1-on-1 meetings only
Location: Four Seasons Hotel, Boston, MA

About CymaBay

CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPAR δ agonist, currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with non-alcoholic steatohepatitis (NASH).

For additional information about CymaBay visit www.cymabay.com.

Contact:

Hans Vitzthum
LifeSci Advisors, LLC

212-915-2568

Hans@LifeSciAdvisors.com



Source: CymaBay Therapeutics, Inc.